Product Or Class Guidances For Biosimilars? Industry Had Its Say
The FDA Requested Feedback On Two Biosimilar Development Questions Back In July
Respondents to the FDA’s questions over biosimilar development did not hold back. So, what is it: product-specific or product class-specific guidance? Or nothing?
